Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Ratio-Tryptophan (02237250). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Tryptophan
Form:
10 of 10 products shown
All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules
Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Apo-Tryptophan · DIN 02248539 · 1 g · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Tryptophan · DIN 02248539
Manufacturer: Apotex Inc.; listing date 2008-06-27
Health Canada: Marketed since 2003-12-09 · brand APO-TRYPTOPHAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 1 G · company Apotex inc · schedule Prescription
DIN 02248539: Apo-Tryptophan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612030; group id 513; item number 1360; lccId None; manufacturer id APX
Source form: Tab; strength: 1g
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.6669; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248539
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72893Interchangeable products
Tryptan · DIN 00654531 · not recorded
Shortage status: resolved shortage (ended April 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248539
Shortage record checked October 6, 2026
Tryptan · DIN 00654531 · 1 g · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Tryptan · DIN 00654531
Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01
Health Canada: Marketed since 2021-06-11 · brand TRYPTAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 1 G · company Bausch health, canada inc. · schedule Prescription
DIN 00654531: Tryptan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612030; group id 513; item number 1360; lccId None; manufacturer id VAL
Source form: Tab; strength: 1g
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00654531
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7264Interchangeable products
Apo-Tryptophan · DIN 02248539 · not recorded
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00654531
Shortage record checked October 6, 2026
Apo-Tryptophan · DIN 02248540 · 500 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Tryptophan · DIN 02248540
Manufacturer: Apotex Inc.; listing date 2008-06-27
Health Canada: Marketed since 2003-12-09 · brand APO-TRYPTOPHAN · ATC N06AX02 TRYPTOPHAN · form Capsule · route Oral · ingredients TRYPTOPHAN 500 MG · company Apotex inc · schedule Prescription
DIN 02248540: Apo-Tryptophan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612028; group id 513; item number 1357; lccId None; manufacturer id APX
Source form: Cap; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.8295; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248540
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72895Interchangeable products
Ratio-Tryptophan · DIN 02240334 · not recorded
Tryptan · DIN 00718149 · not recorded
Shortage status: resolved shortage (ended June 16, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248540
Shortage record checked October 6, 2026
Ratio-Tryptophan · DIN 02240334 · 500 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Ratio-Tryptophan · DIN 02240334
Manufacturer: Ratiopharm Inc.; listing date 2008-12-03
Health Canada: Marketed since 2013-01-03 · brand TEVA-TRYPTOPHAN · ATC N06AX02 TRYPTOPHAN · form Capsule · route Oral · ingredients TRYPTOPHAN 500 MG · company Teva canada limited · schedule Prescription
DIN 02240334: Ratio-Tryptophan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612028; group id 513; item number 1357; lccId None; manufacturer id RPH
Source form: Cap; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4987; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240334
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63873Interchangeable products
Apo-Tryptophan · DIN 02248540 · not recorded
Tryptan · DIN 00718149 · not recorded
Shortage status: active shortage (reported August 7, 2024, last updated August 8, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240334
Shortage record checked October 6, 2026
Tryptan · DIN 00718149 · 500 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Tryptan · DIN 00718149
Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01
Health Canada: Marketed since 2021-06-11 · brand TRYPTAN · ATC N06AX02 TRYPTOPHAN · form Capsule · route Oral · ingredients TRYPTOPHAN 500 MG · company Bausch health, canada inc. · schedule Prescription
DIN 00718149: Tryptan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612028; group id 513; item number 1357; lccId None; manufacturer id VAL
Source form: Cap; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00718149
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7263Interchangeable products
Apo-Tryptophan · DIN 02248540 · not recorded
Ratio-Tryptophan · DIN 02240334 · not recorded
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00718149
Shortage record checked October 6, 2026
Apo-Tryptophan · DIN 02248538 · 500 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Tryptophan · DIN 02248538
Manufacturer: Apotex Inc.; listing date 2008-06-27
Health Canada: Marketed since 2003-12-09 · brand APO-TRYPTOPHAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 500 MG · company Apotex inc · schedule Prescription
DIN 02248538: Apo-Tryptophan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612029; group id 513; item number 1358; lccId None; manufacturer id APX
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.8295; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248538
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72892Interchangeable products
Ratio-Tryptophan · DIN 02240333 · not recorded
Tryptan · DIN 02029456 · not recorded
Shortage status: shortage reported ended June 25, 2026 (report last updated June 25, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248538
Shortage record checked October 6, 2026
Ratio-Tryptophan · DIN 02240333 · 500 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Ratio-Tryptophan · DIN 02240333
Manufacturer: Ratiopharm Inc.; listing date 2008-12-03
Health Canada: Marketed since 2013-01-03 · brand TEVA-TRYPTOPHAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 500 MG · company Teva canada limited · schedule Prescription
DIN 02240333: Ratio-Tryptophan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612029; group id 513; item number 1358; lccId None; manufacturer id RPH
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4987; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240333
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63872Interchangeable products
Apo-Tryptophan · DIN 02248538 · not recorded
Tryptan · DIN 02029456 · not recorded
Shortage status: discontinued (June 16, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240333
Shortage record checked October 6, 2026
Tryptan · DIN 02029456 · 500 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Tryptan · DIN 02029456
Manufacturer: Valeant Canada Ltd.; listing date 2008-06-27
Health Canada: Marketed since 2021-06-11 · brand TRYPTAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 500 MG · company Bausch health, canada inc. · schedule Prescription
DIN 02029456: Tryptan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612029; group id 513; item number 1358; lccId None; manufacturer id VAL
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02029456
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15485Interchangeable products
Apo-Tryptophan · DIN 02248538 · not recorded
Ratio-Tryptophan · DIN 02240333 · not recorded
Shortage status: resolved shortage (ended May 30, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02029456
Shortage record checked October 6, 2026
Apo-Tryptophan · DIN 02458721 · 750 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Tryptophan · DIN 02458721
Manufacturer: Apotex Inc.; listing date 2017-05-31
Health Canada: Marketed since 2017-02-06 · brand APO-TRYPTOPHAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 750 MG · company Apotex inc · schedule Prescription
DIN 02458721: Apo-Tryptophan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612019; group id 513; item number 1359; lccId None; manufacturer id APX
Source form: Tab; strength: 750mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.2883; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02458721
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94588Interchangeable products
Tryptan · DIN 02239327 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02458721
Shortage record checked October 6, 2026
Tryptan · DIN 02239327 · 750 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Tryptan · DIN 02239327
Manufacturer: Valeant Canada Ltd.; listing date 2017-05-31
Health Canada: Marketed since 2021-06-11 · brand TRYPTAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 750 MG · company Bausch health, canada inc. · schedule Prescription
DIN 02239327: Tryptan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281612019; group id 513; item number 1359; lccId None; manufacturer id VAL
Source form: Tab; strength: 750mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239327
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62796Interchangeable products
Apo-Tryptophan · DIN 02458721 · not recorded
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02239327
Shortage record checked October 6, 2026
Other drugs in the same formulary class (28:16:12 Other Psychotropics) and how they are covered
Matched class: 28:16:12 Other Psychotropics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): LITHIUM CARBONATE
28:16:12 Other Psychotropics
1 INDICATIONS
TRYPTAN is indicated:
as a valuable adjunct to antidepressant drug treatment in the management of patients suffering
from depressive disorders (bipolar affective disorders).
https://pdf.hres.ca/dpd_pm/00061741.PDF
PM date: June 9, 2021
Source product: TRYPTAN; DIN 00654531; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Tryptan · DIN 00654531
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00654531
Ratio-Tryptophan · DIN 02240334
Shortage status: active shortage (reported 2024-08-07, last updated 2024-08-08) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240334
Apo-Tryptophan · DIN 02248538
Shortage status: shortage reported ended 2026-06-25 (report last updated 2026-06-25); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248538
Ratio-Tryptophan · DIN 02240333
Shortage status: discontinued (2025-06-16, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240333
Tryptan · DIN 02239327
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02239327
For Apo-Tryptophan, Tryptan, Ratio-Tryptophan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.